[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-429547-105":59,"doc-detail-429547-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","successful-fatherhood-of-males-with-tyrosine-kinase-inhibitor-resistant-chronic-myeloid-leukemia-taking-olverembatinib","Successful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking olverembatinib","","Life expectancy for patients with chronic myeloid leukemia (CML) is increasingly comparable to the general population, making fertility preservation a key quality-of-life issue, particularly for younger patients. Although third-generation (3G) tyrosine kinase inhibitors (TKIs) such as olverembatinib show strong activity in TKI-resistant disease, reproductive safety has remained unclear. Two TKI-resistant male cases achieved sustained deep molecular responses and later conceived healthy children, supporting that olverembatinib exposure does not preclude normal male fertility.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/successful-fatherhood-of-males-with-tyrosine-kinase-inhibitor-resistant-chronic-myeloid-leukemia-taking-olverembatinib/429547/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/successful-fatherhood-of-males-with-tyrosine-kinase-inhibitor-resistant-chronic-myeloid-leukemia-taking-olverembatinib/429547.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is fertility preservation important in chronic myeloid leukemia (CML)?","Question",{"text":112,"@type":113},"As life expectancy in CML approaches that of the general population, fertility preservation becomes a critical quality-of-life concern, especially for younger patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What evidence does the paper provide about olverembatinib and male fertility?",{"text":117,"@type":113},"The report describes two TKI-resistant male patients who achieved sustained deep molecular responses with olverembatinib and subsequently conceived healthy offspring, indicating olverembatinib exposure did not prevent normal male fertility.",{"name":119,"@type":110,"acceptedAnswer":120},"What preclinical concern existed before the reported clinical observations?",{"text":121,"@type":113},"Preclinical data in male rats showed testicular toxicity with seminiferous tubule damage and increased sperm morphological defects after olverembatinib administration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},429547,1790889717,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Annals of Hematology (2025) 104:6435–6437  \n[https://doi.org/10.1007/s00277-025-06722-2](https://doi.org/10.1007/s00277-025-06722-2)  \nCASE REPORT  \nSuccessful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking olverembatinib  \nLu Yu1 · Qian Jiang1,2  \nReceived: 9 October 2025 / Accepted: 1 November 2025 / Published online: 14 November 2025 © The Author(s) 2025  \nAbstract  \nAs life expectancy in patients with chronic myeloid leukemia (CML) approaches that of the general population, fertility preservation has become a critical quality-of-life consideration, especially for younger patients. Although third-generation (3G) tyrosine kinase inhibitors (TKIs), such as olverembatinib, demonstrate potent efficacy against TKI-resistant disease, their reproductive safety profiles remain largely undefined. We report two TKI-resistant male patients who achieved sustained deep molecular responses with olverembatinib and who subsequently conceived healthy offspring with their partners. These cases provide clinical evidence that olverembatinib exposure does not preclude normal male fertility or healthy offspring, emphasizing the need for systematic reproductive safety data on 3G TKIs.  \nKeywords Chronic myeloid leukemia · Tyrosine kinase inhibitor-resistant · Olverembatinib · Fatherhood  \nIntroduction  \nThe successive introduction of tyrosine kinase inhibitors (TKIs), including third-generation (3G) TKIs, has dramatically increased the survival rates of patients with chronic myeloid leukemia (CML) [1–4] . The normalization of life expectancy has led to an increasing focus on quality-of-life issues, including fertility. Approximately 20% of individuals diagnosed with CML in Western countries are younger than 45 years, with a slight male predominance. Notably, the median age of CML onset in Asian populations is 10 to 15 years younger than that in Western populations, making  \nfertility a significant clinical concern in this group [5] .  \nA few studies have reported reduced sperm countsand abnormal sperm morphology after several months of TKI exposure [6] . Some data have suggested that potential gonadotoxic effects are mediated by disruption of the  \n􀀍 Qian Jiang [jiangqian@medmail.com.cn](jiangqian@medmail.com.cn)  \n1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, No. 11 Xizhimen South Street, Beijing, Xicheng District 100044, China  \n2 Peking University People’s Hospital, Qingdao, China  \nhypothalamic–pituitary–gonadal axis. However, preclinical studies and limited clinical data have not consistently demonstrated deleterious effects of TKIs on male fertility, partner pregnancy outcomes, or postnatal development [7, 8] .  \nAlthough the efficacy and tolerability of 3G TKIs have been well characterized, their reproductive safety profile remains largely undefined. Olverembatinib is a novel 3GTKI with potent activity against TKI-resistant CML and Philadelphia chromosome–positive acute lymphoid leukemia [1, 9, 10] . Preclinical data on olverembatinib have revealed that its administration to male rats induces testicular toxicity, characterized by seminiferous tubule atrophy and degeneration of the spermatogenic epithelium. Additionally, the weights of seminal vesicles and coagulating glands decreased in treated animals, and the incidence of sperm morphological defects increased. We report two cases of TKI-resistant male patients who achieved deep molecular responses with olverembatinib and subsequently fathered healthy offspring.  \nCase report  \nCase 1  \nIn May 2007, a 15-year-old boy presented with a 1-week history of abdominal discomfort and a palpable left  \nupper-quadrant mass. The laboratory work-up revealed a white blood cell count of 28 × 10⁹/L and a platelet count of 300 × 10⁹/L, and splenomegaly was confirmed radiologically.","cbCaim3OHOjM1XPr","https://ap.wps.com/l/cbCaim3OHOjM1XPr","pdf",536004,"English","# Abstract\n# Introduction\n# Case report\n## Case 1\n## Case 2","[{\"question\":\"Why is fertility preservation important in chronic myeloid leukemia (CML)?\",\"answer\":\"As life expectancy in CML approaches that of the general population, fertility preservation becomes a critical quality-of-life concern, especially for younger patients.\"},{\"question\":\"What evidence does the paper provide about olverembatinib and male fertility?\",\"answer\":\"The report describes two TKI-resistant male patients who achieved sustained deep molecular responses with olverembatinib and subsequently conceived healthy offspring, indicating olverembatinib exposure did not prevent normal male fertility.\"},{\"question\":\"What preclinical concern existed before the reported clinical observations?\",\"answer\":\"Preclinical data in male rats showed testicular toxicity with seminiferous tubule damage and increased sperm morphological defects after olverembatinib administration.\"}]","Successful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking olverembatinib | PDF",1790650457]